Interleukin-10 Levels are Associated with Doxorubicin-Related Cardiotoxicity in Breast Cancer Patients in a One-Year Follow-Up Study
- 9 February 2021
- journal article
- research article
- Published by Taylor & Francis in Immunological Investigations
- Vol. 51 (4) , 883-898
Abstract
Myocardial toxicity is a common side effect of doxorubicin (DOXO) therapy in breast cancer patients. We hypothesized that DOXO-induced cardiotoxicity may be related to the release of inflammatory c...Keywords
Funding Information
- FAPEMIG (CDS - APQ-01560-15)
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
This publication has 40 references indexed in Scilit:
- Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in MicePLOS ONE, 2012
- Catechin protects against oxidative stress and inflammatory-mediated cardiotoxicity in adriamycin-treated ratsClinical and Experimental Medicine, 2011
- Role of interleukin-10 in breast cancerBreast Cancer Research and Treatment, 2011
- Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasomeCancer Biology & Therapy, 2011
- IL-10 Inhibits Inflammation and Attenuates Left Ventricular Remodeling After Myocardial Infarction via Activation of STAT3 and Suppression of HuRCirculation Research, 2009
- Cardiotoxicity of Cancer TherapyJournal of Clinical Oncology, 2005
- Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: A ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudyAmerican Heart Journal, 2005
- Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout MiceCirculation, 2004
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000